TheStreet reckons Regeneron (REGN) is a "buy," upgrading it from "hold." The site's Ratings...

|About: Regeneron Pharmaceuticals... (REGN)|By:, SA News Editor

TheStreet reckons Regeneron (REGN) is a "buy," upgrading it from "hold." The site's Ratings department cites Regeneron's robust revenue, net income and EPS growth, its solid stock price performance, and largely solid financial position. These strengths outweigh Regeneron's weak operating cash flow.